Abbott Laboratories [NYSE: ABT] gained 0.65% or 0.71 points to close at $110.00 with a heavy trading volume of 7929572 shares. The company report on June 3, 2021 that Abbott Confirms Capacity to Support Expanded Use of HeartMate 3™ Heart Pump.
– Abbott has the capacity and supply to support increased demand for mechanical circulatory support (MCS) devices following Medtronic’s decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD).
– Access to MCS devices are critical for advanced heart failure patients and can improve survival, clinical outcomes and quality of life.
It opened the trading session at $109.98, the shares rose to $110.88 and dropped to $109.72, the range by which the price of stock traded the whole day. The daily chart for ABT points out that the company has recorded 2.30% gains over the past six months. However, it is still -27.67% lower than its most recent low trading price.
If we look at the average trading volume of 5.75M shares, ABT reached to a volume of 7929572 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Abbott Laboratories [ABT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $136.48 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Barclays have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 25, 2021. While these analysts kept the previous recommendation, Atlantic Equities raised their target price to Neutral. The new note on the price target was released on April 15, 2021, representing the official price target for Abbott Laboratories stock. Previously, the target price had yet another raise to $140, while BTIG Research analysts kept a Buy rating on ABT stock.
The Average True Range (ATR) for Abbott Laboratories is set at 2.37, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 5.23. The Price to Book ratio for the last quarter was 5.82, with the Price to Cash per share for the same quarter was set at 4.72. Price to Free Cash Flow for ABT in the course of the last twelve months was 39.96 with Quick ratio for the last quarter at 1.30.
Trading performance analysis for ABT stock
Abbott Laboratories [ABT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.70. With this latest performance, ABT shares dropped by -7.40% in over the last four-week period, additionally plugging by 2.30% over the last 6 months – not to mention a rise of 22.41% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 36.72, with the RSI for the last a single of trading hit 36.60, and the three-weeks RSI is set at 38.15 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 118.64, while it was recorded at 108.24 for the last single week of trading, and 113.43 for the last 200 days.
Abbott Laboratories [ABT]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of +15.29 and a Gross Margin at +50.21. Abbott Laboratories’s Net Margin is presently recorded at +12.86.
Return on Total Capital for ABT is now 10.24, given the latest momentum, and Return on Invested Capital for the company is 8.83. Return on Equity for this stock inclined to 13.93, with Return on Assets sitting at 6.34. When it comes to the capital structure of this company, Abbott Laboratories [ABT] has a Total Debt to Total Equity ratio set at 60.67. Additionally, ABT Total Debt to Total Capital is recorded at 37.76, with Total Debt to Total Assets ending up at 27.42. Long-Term Debt to Equity for the company is recorded at 59.26, with the Long-Term Debt to Total Capital now at 36.89.
Reflecting on the efficiency of the workforce at the company, Abbott Laboratories [ABT] managed to generate an average of $40,817 per employee. Receivables Turnover for the company is 5.85 with a Total Asset Turnover recorded at a value of 0.49.Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.80.
Abbott Laboratories [ABT]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Abbott Laboratories posted 0.57/share EPS, while the average EPS was predicted by analysts to be reported at 0.42/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 35.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 12.82%.
An analysis of insider ownership at Abbott Laboratories [ABT]
There are presently around $145,386 million, or 76.20% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 146,567,914, which is approximately -0.479% of the company’s market cap and around 0.70% of the total institutional ownership; BLACKROCK INC., holding 134,074,306 shares of the stock with an approximate value of $14.75 billion in ABT stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $9.44 billion in ABT stock with ownership of nearly -0.698% of the company’s market capitalization.
Positions in Abbott Laboratories stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,133 institutional holders increased their position in Abbott Laboratories [NYSE:ABT] by around 51,065,623 shares. Additionally, 1,122 investors decreased positions by around 35,999,143 shares, while 362 investors held positions by with 1,234,624,549 shares. The mentioned changes placed institutional holdings at 1,321,689,315 shares, according to the latest SEC report filing. ABT stock had 161 new institutional investments in for a total of 7,170,911 shares, while 94 institutional investors sold positions of 2,620,455 shares during the same period.